Schroder Investment Management Group bought a new stake in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 354,900 shares of the specialty pharmaceutical company’s stock, valued at approximately $52,571,000. Schroder Investment Management Group owned about 0.59% of Jazz Pharmaceuticals as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in JAZZ. FMR LLC lifted its stake in shares of Jazz Pharmaceuticals by 11.4% during the 2nd quarter. FMR LLC now owns 8,290,410 shares of the specialty pharmaceutical company’s stock valued at $1,289,159,000 after buying an additional 849,348 shares in the last quarter. Vanguard Group Inc. lifted its position in Jazz Pharmaceuticals by 3.4% during the second quarter. Vanguard Group Inc. now owns 4,677,223 shares of the specialty pharmaceutical company’s stock valued at $727,308,000 after acquiring an additional 153,908 shares during the last quarter. Bank of New York Mellon Corp raised its holdings in shares of Jazz Pharmaceuticals by 7.7% in the third quarter. Bank of New York Mellon Corp now owns 1,486,426 shares of the specialty pharmaceutical company’s stock worth $217,390,000 after buying an additional 105,838 shares during the last quarter. JPMorgan Chase & Co. raised its holdings in shares of Jazz Pharmaceuticals by 41.2% in the second quarter. JPMorgan Chase & Co. now owns 1,405,408 shares of the specialty pharmaceutical company’s stock worth $218,540,000 after buying an additional 410,031 shares during the last quarter. Finally, Renaissance Technologies LLC raised its holdings in shares of Jazz Pharmaceuticals by 3.5% in the second quarter. Renaissance Technologies LLC now owns 1,201,500 shares of the specialty pharmaceutical company’s stock worth $186,833,000 after buying an additional 40,537 shares during the last quarter. Institutional investors own 91.28% of the company’s stock.

Shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) opened at $139.74 on Friday. The company has a quick ratio of 2.94, a current ratio of 3.10 and a debt-to-equity ratio of 0.63. Jazz Pharmaceuticals PLC has a 12 month low of $99.28 and a 12 month high of $163.75. The stock has a market capitalization of $8,369.69, a PE ratio of 17.52, a P/E/G ratio of 0.90 and a beta of 1.00.

In related news, SVP Iain Mcgill sold 8,000 shares of the stock in a transaction that occurred on Friday, November 17th. The shares were sold at an average price of $133.42, for a total transaction of $1,067,360.00. Following the completion of the sale, the senior vice president now owns 28,383 shares of the company’s stock, valued at $3,786,859.86. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Bruce C. Cozadd sold 1,000 shares of the stock in a transaction that occurred on Tuesday, September 12th. The shares were sold at an average price of $153.52, for a total transaction of $153,520.00. The disclosure for this sale can be found here. Insiders have sold 10,352 shares of company stock valued at $1,417,763 over the last quarter. Company insiders own 4.30% of the company’s stock.

JAZZ has been the topic of a number of research reports. BidaskClub lowered shares of Jazz Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, August 3rd. Zacks Investment Research raised shares of Jazz Pharmaceuticals from a “hold” rating to a “buy” rating and set a $174.00 price target on the stock in a research note on Tuesday, August 8th. Janney Montgomery Scott reaffirmed a “buy” rating and set a $192.00 target price (up from $180.00) on shares of Jazz Pharmaceuticals in a research note on Wednesday, August 9th. Royal Bank Of Canada reaffirmed a “buy” rating on shares of Jazz Pharmaceuticals in a research note on Wednesday, August 9th. Finally, Deutsche Bank set a $175.00 price target on Jazz Pharmaceuticals and gave the company a “buy” rating in a research note on Wednesday, August 9th. Two research analysts have rated the stock with a sell rating, five have given a hold rating and eighteen have given a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $180.13.

TRADEMARK VIOLATION NOTICE: This news story was posted by Daily Political and is the sole property of of Daily Political. If you are viewing this news story on another site, it was copied illegally and reposted in violation of United States & international copyright & trademark legislation. The original version of this news story can be viewed at https://www.dailypolitical.com/2017/12/01/schroder-investment-management-group-takes-52-57-million-position-in-jazz-pharmaceuticals-plc-jazz.html.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.

Want to see what other hedge funds are holding JAZZ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ).

Institutional Ownership by Quarter for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals PLC and related companies with MarketBeat.com's FREE daily email newsletter.